Your session is about to expire
← Back to Search
Virus Therapy
Procedure: Heart Transplantation for Heart Failure
N/A
Waitlist Available
Research Sponsored by Loma Linda University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 15 months
Awards & highlights
Study Summary
This trial will test whether it is safe and effective to transplant hearts from donors with HCV into recipients who do not have the virus.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 15 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~15 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Patient Survival Rate
Trial Design
1Treatment groups
Experimental Treatment
Group I: Experimental: Recipient of HCV positive heart graftExperimental Treatment1 Intervention
A single center, open-label, pilot study examining 10 adult HCV negative heart transplant subjects who will receive an HCV infected graft. Target start date for antiviral therapy will be within 3 months after heart transplantation.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Procedure: Heart Transplantation
2020
N/A
~10
Find a Location
Who is running the clinical trial?
Loma Linda UniversityLead Sponsor
306 Previous Clinical Trials
260,982 Total Patients Enrolled
2 Trials studying Heart Failure
74 Patients Enrolled for Heart Failure
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger